Added to YB: 2024-08-30
Pitch date: 2024-07-14
GRAL [bullish]
GRAIL, Inc.
+214.2%
current return
Author Info
No bio for this author
Company Info
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Market Cap
$1.8B
Pitch Price
$15.00
Price Target
30.00 (-36%)
Dividend
N/A
Sector
Biotechnology
Category
special_situation
GRAIL, Inc. - $GRAL
GRAL: Illumina spinoff w/ $1B cash for early cancer detection blood test. 180K tests sold, $93M rev in '23. Key trials NHS-Galleri & PATHFINDER 2 for FDA approval. Risks: cash burn $500M/yr. PT $30 (2x cash). Long-term potential $5-10B rev, 30% margin. Catalysts: acquisition, PMA approval.
Read full article (3 min)